Pierre Labauge
Overview
Explore the profile of Pierre Labauge including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
270
Citations
4471
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Seze J, Labauge P, Liblau R, Martinez M, Moreau T, Suchet L, et al.
Adv Ther
. 2025 Feb;
PMID: 39969782
Introduction: Dimethyl fumarate (DMF) has demonstrated a favorable benefit-risk profile in patients with relapsing-remitting multiple sclerosis (RRMS). Some patients may develop lymphopenia on DMF; therefore, LymphoTEC evaluated absolute lymphocyte count...
2.
Lorscheider J, Signori A, Subramaniam S, Benkert P, Vukusic S, Trojano M, et al.
J Neurol Neurosurg Psychiatry
. 2024 Dec;
PMID: 39643429
Background: Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains...
3.
Carmona S, Aghzadi J, Vincent T, Labauge P, Carra-Dalliere C, Lehmann S, et al.
Inflammation
. 2024 Dec;
PMID: 39641859
Multiple sclerosis (MS) is a complex, chronic inflammatory disease of the central nervous system, where immune dysregulation plays a critical role. We sought to explore the modulation of the pro-inflammatory...
4.
Lefort M, Dejardin O, Berger E, Camdessanche J, Ciron J, Clavelou P, et al.
Mult Scler
. 2024 Dec;
31(1):69-80.
PMID: 39618051
Background: We hypothesized that differences in access to disease-modifying treatments (DMTs) could explain the association between socioeconomic status and disability progression in multiple sclerosis (MS). Objective: This study aimed to...
5.
Lefort M, Dejardin O, Berger E, Camdessanche J, Ciron J, Clavelou P, et al.
Mult Scler
. 2024 Nov;
31(1):59-68.
PMID: 39614776
Background: Studies have reported an association between socioeconomic status and disability progression in multiple sclerosis (MS), but findings using the pre-MS individual socioeconomic status are missing. Objective: The objective was...
6.
Labauge P, Creange A, Moreau T, Nouvet-Gire J, Pedespan B, Heinzlef O, et al.
Neurol Ther
. 2024 Nov;
14(1):177-192.
PMID: 39527163
Introduction: Treatment persistence and adherence are essential for achieving therapeutic goals in patients with multiple sclerosis (MS). OroSEP is an independent patient-support program (PSP) in France for patients with relapsing-remitting...
7.
Hay M, Rollot F, Casey R, Kerbrat A, Edan G, Mathey G, et al.
Neurology
. 2024 Sep;
103(8):e209886.
PMID: 39321406
Background And Objectives: Although rituximab failed to demonstrate a significant effect on disability progression in primary progressive multiple sclerosis (PPMS), ocrelizumab succeeded. Our main objective was to analyze confirmed disability...
8.
Landes-Chateau C, Ricigliano V, Mondot L, Thouvenot E, Labauge P, Louapre C, et al.
Mult Scler
. 2024 Sep;
30(10):1278-1289.
PMID: 39246289
Background: Choroid plexus (ChP) enlargement is an emerging radiological biomarker in multiple sclerosis (MS). Objectives: This study aims to assess ChP volume in a large cohort of patients with radiologically...
9.
Serum NfL and GFAP are weak predictors of long-term multiple sclerosis prognosis: A 6-year follow-up
Ayrignac X, Aouinti S, Vincent T, Carra-Dalliere C, Charif M, Duflos C, et al.
Mult Scler Relat Disord
. 2024 Jul;
89:105747.
PMID: 39053395
Background: Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are promising biomarkers that might be associated with clinical and radiological markers of multiple sclerosis (MS) severity. However,...
10.
Gavoille A, Rollot F, Casey R, Kerbrat A, Le Page E, Bigaut K, et al.
JAMA Neurol
. 2024 Jul;
81(8):814-823.
PMID: 38949816
Importance: Understanding the association between clinically defined relapses and radiological activity in multiple sclerosis (MS) is essential for patient treatment and therapeutic development. Objective: To investigate clinical events identified as...